1. Cerus to present at Goldman Sachs 2025 Healthcare Conference in June. 2. Company aims to be a leader in global blood products. 3. INTERCEPT Blood System has FDA approval and CE mark for key components. 4. INTERCEPT red blood cell system under review in Europe and clinical trials in U.S.
Cerus' presentation at a prestigious conference can enhance visibility, attracting investor interest. Historically, significant presentations often correlate with stock price increases due to heightened investor optimism.
The scheduled presentation may lead to increased investor interest and potential stock price growth, impacting Cerus' immediate market presence.
The immediate impact is expected around the conference date, as investor sentiment will be influenced by the presentation. Following similar past occurrences, market reactions can be swift.
CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (Nasdaq: CERS) announced today that members of the management team are scheduled to present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami, Florida, on Wednesday, June 11, 2025, at 8:40 a.m. Eastern Time.
A live webcast of the presentation can be accessed via the Events & Presentation section of Cerus’ Investor Relations website at ir.cerus.com. A replay of the webcast will be available on Cerus Investor Relations website shortly after the event for 30 days.
ABOUT CERUS
Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the U.S., the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the U.S. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.